Indian drug regulators have uncovered a significant counterfeit drug operation involving fake versions of Mounjaro, a widely used medication for diabetes and weight management. More than 260 suspected counterfeit injection pens were seized by authorities, highlighting growing concerns over the circulation of fake pharmaceutical products in India’s rapidly expanding healthcare market.
The operation was carried out by officials from the Haryana Food and Drug Control Administration, who intercepted a vehicle on the outskirts of New Delhi and recovered the suspected fake pens. During the कार्रवाई, two individuals were arrested for allegedly manufacturing and distributing the counterfeit drugs. Investigators revealed that the main आरोपी did not possess a valid pharmaceutical licence and was producing the pens at a private property, raising serious questions about regulatory violations and public safety risks.
According to officials, the accused sourced key raw materials, including peptide compounds used in the drug formulation, from vendors on the Alibaba platform. Authorities also recovered large quantities of packaging materials, including labels designed to mimic genuine Mounjaro products, indicating a well-organised attempt to replicate branded medication.
The counterfeit pens were reportedly sold through the IndiaMART platform at prices approximately 27 per cent lower than the original drug, making them attractive to unsuspecting buyers. However, discrepancies in packaging, such as variations in font size and labelling, along with improper storage conditions—particularly failure to maintain required temperature controls—raised suspicions among regulators.
The seized materials and equipment are estimated to be worth around Rs 70 lakh, and samples of the suspected counterfeit drugs have been sent to government laboratories for testing to confirm their composition and authenticity. Meanwhile, the arrested individuals have been placed in judicial custody as the investigation continues to trace the full extent of the network involved.
The case comes at a time when India’s obesity and diabetes treatment market is witnessing rapid growth, driven by rising demand for advanced therapies. Mounjaro, introduced in India in 2025, has quickly become one of the country’s top-selling drugs by value, making it a prime target for counterfeit operations.
Pharmaceutical company Eli Lilly, which manufactures Mounjaro, stated that it takes patient safety very seriously and supports regulatory action against the distribution of fake medicines. The incident underscores the urgent need for stricter monitoring of online marketplaces and supply chains to prevent the spread of potentially dangerous counterfeit drugs.
